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Proteasome inhibitors (e.g., bortezomib, MG132) are known to enhance adeno-associated virus (AAV) transduction; however,
whether this results from pleotropic proteasome inhibition or off-target serine and/or cysteine protease inhibition remains un-
resolved. Here, we examined recombinant AAV (rAAV) effects of a new proteasome inhibitor, carfilzomib, which specifically
inhibits chymotrypsin-like proteasome activity and no other proteases. We determined that proteasome inhibitors act on rAAV
through proteasome inhibition and not serine or cysteine protease inhibition, likely through positive changes late in
transduction.
Adeno-associated virus (AAV) is frequently utilized as a genedelivery vector for clinical application; thus, several ap-
proaches have been undertaken to increase efficacy, including
transgene optimization (1–3), capsid alteration (reviewed in ref-
erence 4), and drug treatments to enhance transduction (5–13).
Proteasome inhibitors (PIs) were first described to enhance re-
combinant AAV (rAAV) polarized airway cell transduction (6),
and since then PIs, including N-acetyl-L-leucinyl-L-leucinyl-nor-
leucinal (LLnL) (6, 14–19), MG132 (5, 6, 8, 11, 14, 17, 20–24),
bortezomib (11, 25), and celastrol (26), have been observed to
enhance transduction in many cell types both in vitro and in vivo.
Nevertheless, questions remain regarding the mechanism of this
enhancement. Although ubiquitinated rAAV2 capsid proteins ac-
cumulate after PI treatment, suggesting PIs prevent the degrada-
tion of ubiquitinated AAV capsids and lead to increased transgene
expression, some level of capsid dissociation (6) or phosphoryla-
tion (27, 28) appears to be necessary for ubiquitination, and the
role of the proteasome in these effects has not been directly exam-
ined. In addition to proteasome inhibition, PIs are commonly
observed to inhibit other proteases, such as cysteine (MG-132)
and serine (MG-132 and bortezomib) proteases (29). These pro-
teases have very different cellular roles from the proteasome,
which degrades ubiquitinated cytoplasmic and nuclear proteins,
including lysosomal degradation and calcium-dependent intra-
cellular signaling. In fact, the in vivo peripheral neuropathy caused
by bortezomib is the result of serine protease inhibition leading to
neurotoxicity (30), demonstrating the importance of off-target
effects with clinically relevant dosing of PIs. The broad range of
inhibition caused by PIs has caused many in the field of rAAV
research to hypothesize that the effects of PIs on rAAV transduc-
tion are due to off-target effects of PIs and not inhibition of the
proteasome. In addition, whether the enhancement of rAAV
transduction occurs through proteasome inhibition or protease
inhibition, it is also unclear whether the effects of PIs prevent the
degradation of rAAV virions or whether they cause a positive
change in transduction.
The promiscuity of so-called “first-generation” PIs (i.e., those
available before carfilzomib) led to the development of new PIs
with restricted specificity. Proteases, including the proteasome,
act through a nucleophilic attack by their active site residue, which
can be serine, cysteine, or threonine, or by water in the case of
aspartic and metalloproteases. The protease’s active site residue is
used to classify the protease (e.g., serine protease). Unlike other
classes of proteases, active site threonine of the proteasome is the
N-terminal residue of each catalytic subunit, exposing the amino
group to possible reactivity (31). Carfilzomib, a second-genera-
tion PI, relies on this amino group to form a morpholino, cova-
lently inhibiting cleavage (32), and so cannot inhibit other pro-
teases (33, 34). In fact, carfilzomib highly inhibits only the
chymotrypsin-like activity of the proteasome (34), making it a
useful tool for examining the importance of proteasome inhibi-
tion on enhancement of rAAV transduction and addressing the
hypothesis stated above that PIs act on rAAV transduction
through off-target effects on other proteases. To determine
whether the enhancement of rAAV transduction observed with PI
treatment occurs from proteasome inhibition or from inhibition
of other proteases, we utilized several PIs as well as cysteine and
serine protease inhibitors and assessed their effect on rAAV trans-
duction.
Carfilzomib enhances rAAV2 transduction in vitro. To ad-
dress the question of whether a specific PI is sufficient to enhance
rAAV transduction, we utilized three PIs, MG132, bortezomib,
and carfilzomib (Selleck Chemicals), and an rAAV serotype 2
(rAAV2) vector expressing luciferase or enhanced green fluores-
cent protein (EGFP) transgenes (35). We coadministered the
drugs with 1,000 vector genomes per cell (vg/cell) rAAV2 to HeLa
cells and compared their effects on transduction at 24 h (8). Using
luciferase vector, we determined that all of these PIs enhanced
rAAV2 transduction at a range of doses, although we observed
shifts in the curves that correlate with differing 50% inhibitory
concentration (IC50) values (bortezomib, 0.6 nM; carfilzomib, 5
nM; and MG132, 100 nM) (36–38) (Fig. 1A). To differentiate
between the numbers of cells transduced and the level of their
transduction, we treated with 1 M PI, transduced with 500 vg/
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cell rAAV2-EGFP, and assayed EGFP expression by flow cytom-
etry (10). The PIs enhanced both the percentage of cells trans-
duced (Fig. 1B) and their fluorescence intensity (Fig. 1C). This
enhancement can also be observed visually (Fig. 1D). Carfil-
zomib’s transduction enhancement suggests that proteasome in-
hibition is sufficient for PI effects on rAAV transduction, as this is
carfilzomib’s only activity. Furthermore, the similar enhancement
observed between bortezomib and carfilzomib suggests that the
enhancement from bortezomib may be due primarily to protea-
some inhibition.
Serine and cysteine protease inhibition does not enhance
rAAV2 transduction. As we found proteasome inhibition suffi-
cient for the enhancement of rAAV transduction, we asked
whether serine protease inhibition, observed with MG132 and
bortezomib, or cysteine protease inhibition, observed with
MG132, have effects on rAAV2 transduction. We treated HeLa
cells twice with phenylmethanesulfonyl fluoride (PMSF) to in-
hibit serine proteases as has been described (39), coadministered
1,000 vg/cell rAAV2 with the second dose, and analyzed transduc-
tion by luciferase assay at 24 h. We observed no increases in rAAV2
transduction from treatment with a 1,000-fold range of PMSF
doses with a maximum dose 10-fold over PMSF’s working con-
centration (Fig. 2A), suggesting that serine protease inhibition
does not enhance rAAV2 transduction. We confirmed the ability
of PMSF to inhibit serine proteases at these concentrations with a
colorimetric trypsin activity assay (BioVision Inc.), which mea-
sured cleavage of a trypsin substrate over time (Fig. 2B). To inves-
tigate whether cysteine proteases affect rAAV transduction, we
treated cells with E-64 and assayed transduction as described
above. rAAV2 transduction did not change over a 10,000-fold
range of E-64 doses with a maximum dose 10- to 100-fold over
E-64’s working concentration (Fig. 2C), suggesting that cysteine
protease inhibition also does not enhance rAAV2 transduction.
We confirmed the ability of E-64 to inhibit cysteine proteases at
FIG 1 Carfilzomib enhances rAAV2 transduction. (A) HeLa cells were cotreated with the indicated dose of bortezomib, carfilzomib, MG132, or a dimethyl
sulfoxide (DMSO) vehicle control and transduced with 1,000 vg/cell rAAV2-luciferase. Transduction at 24 h is indicated as normalized luciferase activity and fold
values to the vehicle-treated group. (B and C) HeLa cells were cotreated with 1 M PI and 500 vg/cell rAAV2-EGFP, and transduction was analyzed by flow
cytometry at 24 h. The percentage of cells transduced (B) and median fluorescence intensity of the transduced cells (C) are indicated. (D) Bright-field and EGPF
fluorescence images at 24 h postransduction of cells treated as described for panels B and C, visually indicating transduction. Data shown are representative of
three independent experiments. Error bars represent one standard deviation (SD). *, P  0.05 versus the vehicle control based on the Kruskal-Wallis test.
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these concentrations with a luminescent calpain assay (Promega),
which measured cleavage of a luminescent substrate in the pres-
ence and absence of E-64 (Fig. 2D). Although cathepsins B and L
(cysteine proteases) have been suggested to be important for
rAAV transduction (40), we also observed no decreases in trans-
duction with E-64 treatment. This may be due to a difference in
species, as the interaction of cathepsins with rAAV was identified
in murine cells, whereas we are using human cells. Nevertheless, as
PI inhibition of these proteases would only decrease transduction,
cysteine protease inhibition is unlikely to be the mechanism by
which PIs enhance rAAV transduction. Taken together, these data
suggest that enhancement of rAAV transduction by PIs is not due
to off-target effects on other proteases.
Bortezomib and carfilzomib act on rAAV transduction
through the same mechanism. Our results thus far suggest that
proteasomal inhibition is responsible for enhancement of rAAV
transduction after PI treatment. To investigate this hypothesis
further, we determined whether bortezomib and carfilzomib are
both effective on several different AAV serotypes. We treated
HeLa cells with 1 M bortezomib or carfilzomib and 20,000 vg/
cell rAAV6, 100,000 vg/cell rAAV8, or 100,000 vg/cell rAAV9 and
assayed transduction by flow cytometry at 24 h. The enhancement
of the percentage of cells transduced was similar in all serotypes
between bortezomib and carfilzomib, although carfilzomib en-
hanced fluorescence intensity more for some serotypes (Fig. 3A),
strengthening the hypothesis that bortezomib and carfilzomib act
through the same mechanism. Furthermore, to our knowledge,
this is the first report of rAAV9 enhancement by PIs. To assess
directly whether bortezomib and carfilzomib act through the
same mechanism, we performed an exchange experiment where
we treated cells with bortezomib or carfilzomib in combination,
transduced with rAAV2 as before, and assayed transduction at 24
h. There were no increases or decreases in transduction from com-
bining these two drugs (Fig. 3B), suggesting they can be used in-
terchangeably. Combined with our other data, this suggests that
bortezomib and carfilzomib both act to enhance rAAV transduc-
tion through proteasome inhibition.
Consequently, two hypotheses can be drawn for how protea-
some inhibition enhances rAAV transduction: (i) proteasome in-
hibition prevents the degradation of rAAV capsids, increasing the
rAAV pool available to complete transduction; (ii) as misfolded
protein responses can enhance rAAV transduction (41), a general
misfolded protein response and/or ubiquitination of rAAV cap-
sids facilitates late steps in transduction. To address these hypoth-
eses, we treated HeLa cells with bortezomib or carfilzomib and
rAAV2 as described before and assayed intracellular vector ge-
nome copy number at 24 h by quantitative PCR (qPCR) (10). The
copy number was increased 2.3-fold and 1.8-fold by bortezomib
FIG 2 Serine and cysteine protease inhibition does not enhance rAAV2 transduction. (A) HeLa cells were treated 3 h prior to and at the time of transduction with
the indicated dose of PMSF, a serine protease inhibitor, or an ethanol vehicle control and transduced with 1,000 vg/cell rAAV2-luciferase. Transduction is
indicated as normalized luciferase activity. The “Vehicle L” group corresponds to treatments with 10 to 1,000 M, while the “Vehicle H” group corresponds to
treatment with 10,000 M. (B) Indicated concentrations of PMSF or vehicle were combined with 0.002% trypsin and incubated at 30 min at room temperature.
Solutions were diluted 1:10 in assay buffer and combined with trypsin substrate in quadruplicate. Average absorbance at 415 nm is shown for 60 readings at 60-s
intervals. (C) HeLa cells were treated as described for panel A, with E-64, a cysteine protease inhibitor, or a DMSO vehicle control. Transduction is indicated as
normalized luciferase activity. (D) Indicated concentrations of E-64 or vehicle control were combined with 20 nM human calpain 1 (BioVision), incubated at
room temperature for 10 min, and combined with Calpain-Glo luciferase reagent (Promega) with 2 mM CaCl2. E-64 activity is indicated as relative light units.
Data shown are representative of three independent experiments. Error bars represent one SD.
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and carfilzomib treatment, respectively (Fig. 3C); however, this
was much smaller than the 28-fold and 23-fold transduction in-
creases observed with bortezomib and carfilzomib (Fig. 1A).
These data suggest the enhancement of transduction observed is
unlikely to be directly due to capsid retention (hypothesis i). In-
stead, it is more likely that the buildup of ubiquitinated capsid or
a misfolded protein response led to increased favorability in late
transduction steps. This agrees with previous results demonstrat-
ing increased nuclear localization of virus following PI treatment
(6, 11, 17, 23, 26, 27) and specifically increased nucleolar localiza-
tion (8). Furthermore, we previously reported that treatment with
arsenic trioxide leads to increased transduction through stabiliza-
tion of perinuclear rAAV capsids and that this effect was distin-
guishable from PI effects (10). Taken with our current results, this
suggests that, while arsenic trioxide is directly influencing trans-
duction through the retention of capsids that would otherwise be
degraded, PIs are influencing transduction through a modifica-
tion secondary to degradation, explaining their differing effects.
Carfilzomib is less successful at enhancing rAAV transduc-
tion in vivo than bortezomib. As carfilzomib and bortezomib
demonstrate similar rAAV transduction enhancement in vitro, we
tested carfilzomib’s ability to enhance rAAV2 transduction in vivo
to determine whether proteasome inhibition is sufficient for en-
hancement of rAAV transduction in vivo. We utilized rAAV2, a
liver-tropic vector, as the majority of AAV biology has been stud-
ied with this serotype; however, pharmacokinetic studies with
carfilzomib demonstrate low activity in the liver due to drug me-
tabolism (34). Therefore, we expected less enhancement of rAAV
transduction in the liver with carfilzomib than with bortezomib.
All in vivo experiments were approved by and conducted in accor-
dance with the policies of the University of North Carolina at
Chapel Hill’s Institutional Animal Care and Use Committee. We
coadministered either 0.5 mg bortezomib/kg of body weight or 1
mg carfilzomib/kg, a similar molar dose, and 1  1011 vg/mouse
rAAV2 retro-orbitally into age-matched female BALB/c mice
(Jackson Laboratories) (11) and assayed transduction through
live luciferase imaging (10). No acute liver toxicity occurred with
the vehicle or either of the proteasome inhibitors at this dose (Fig.
4A). We observed enhanced transduction from both bortezomib
and carfilzomib treatment at 7 days postransduction (Fig. 4B),
which quantified as 12.4-fold and 2.7-fold enhancements, respec-
tively (Fig. 4C). At day 14, bortezomib mice maintained higher
transduction than vehicle mice; however, carfilzomib and vehicle
mice demonstrated similar transduction (Fig. 4D). Ex vivo quan-
tification of transduction by luciferase assay and vector genome
copy number (10) confirmed the live imaging data (Fig. 4E). De-
spite the expected lesser effects of carfilzomib than of bortezomib
in the liver, these data demonstrate that proteasome inhibition is
sufficient for the enhancement of rAAV transduction in vivo. In
addition, this suggests that, although carfilzomib is not ideal for in
vivo rAAV transduction enhancement in the liver, other second-
generation, highly specific PIs should be evaluated for this pur-
pose as they become available.
Conclusions. Overall, our data demonstrate that proteasome
inhibition is sufficient for rAAV transduction enhancement, and
serine and cysteine protease inhibition is unlikely to contribute to
this enhancement. These data will alter the prevailing view in the
field that the PIs act on rAAV transduction through off-target
effects and instead demonstrate that they act through inhibition of
the proteasome. Furthermore, the strategies employed to address
these questions could now be applied to other viruses which are
thought to be affected by proteasomal activity, such as hepatitis B
virus or herpes simplex virus (42, 43). Additionally, the transduc-
tion increase seems to be secondary to prevention of rAAV capsid
degradation and is instead due to a positive change in late stages of
transduction. Furthermore, although carfilzomib is not ideal for
FIG 3 Bortezomib and carfilzomib act on rAAV2 transduction through the
same mechanism. (A) HeLa cells were treated with 1 M bortezomib, carfil-
zomib, or vehicle control and 20,000 vg/cell rAAV6-EGFP, 100,000 vg/cell
rAAV8-EGFP, or 100,000 vg/cell rAAV9-EGFP, and transduction was assayed
by flow cytometry at 24 h postransduction. Transduction is indicated as fold
values of percentages of cells transduced and median fluorescence intensities
of vehicle control groups. (B) HeLa cells were treated with the indicated doses
(M) of bortezomib and carfilzomib or a vehicle control and 1,000 vg/cell
rAAV2-luciferase. Transduction is indicated as normalized luciferase activity.
(C) HeLa cells were treated as described for Fig. 1B, and intracellular vector ge-
nome copy number was analyzed at 24 h postransduction by qPCR. Data are
indicated as fold values of vg/cell of the vehicle control. Data shown in panels A
and B are representative of three independent experiments. Data shown in panel C
are the means from three independent experiments. Error bars represent one SD.
*, P  0.05 versus the vehicle control group based on the Kruskal-Wallis test.
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FIG 4 Bortezomib is more efficient at enhancing rAAV2 transduction in vivo than carfilzomib. Female BALB/c mice were treated with 1E11 vg/mouse
rAAV2-luciferase and 0.5 mg bortezomib/kg, 1 mg carfilzomib/kg, or DMSO vehicle control. (A) Serum was collected from mice at 24 h posttreatment,
and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured. Individual animals are indicated by diamonds, and the
mean is indicated by bars. Transduction was assayed by live imaging at 7 days postransduction (B), and light output from the area of the liver was
quantified (C). (D) Transduction at 13 days was assayed by live imaging. (E) At 14 days, livers were harvested; transduction is indicated by normalized
luciferase activity. (F) Vector genome copy number was assayed by qPCR. Error bars represent one SD. *, P  0.05 versus the vehicle control based on the
Kruskal-Wallis test.
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enhancing rAAV-mediated liver transduction, our data suggest
that other second-generation PIs in development, such as
ONX0912, MLN9708, and marizomib (44), should be examined
for enhancement of rAAV transduction in vivo. As these PIs may
have fewer side effects than bortezomib, this may become impor-
tant for the enhancement of rAAV clinical gene therapy.
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